Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Expenses:
Research and development	$ 5,076	$ 1,499
General and administrative	3,010	2,558
Total operating expenses	8,086	4,057
Operating loss	(8,086)	(4,057)
Other income:
Investment income, net	23	71
Total other income	23	71
Net loss	(8,063)	(3,986)
Less - net income attributable to noncontrolling interests	0	4
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (8,063)	$ (3,990)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)	$ (0.19)	$ (0.38)
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)	$ (0.19)	$ (0.38)
Weighted average common shares outstanding
Basic shares	42,117	10,623
Diluted shares	42,117	10,623